Partner Brent Babcock was interviewed in “Biopharmas Should Stay Course as High Court Mulls Patent Reviews,” an article published in Bloomberg BNA.
Excerpt: The U.S. Supreme Court is set to rule in 2018 on whether a federal patent agency review procedure is constitutional, potentially upending administrative reviews of biopharma and medical technology patents.